Cetuximab and vemurafenib plus FOLFIRI (5-fluorouracil/leucovorin/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): An open-label, single-arm, phase II trial
Zhan Wang, Bao‐Dong Qin, Chen-Yang Ye, Miaomiao Wang, Lingyan Yuan, Wei-Ping Dai, Li Sun, Ke Liu, Wenxing Qin, Xiao‐Dong Jiao, Xing-Nan Li, Yuan‐Sheng Zang
Topics & Concepts
MedicineCetuximabInternal medicineIrinotecanFOLFIRIVemurafenibOncologyNeutropeniaColorectal cancerPopulationClinical endpointPhases of clinical researchPanitumumabProgression-free survivalGastroenterologyCancerClinical trialChemotherapyMetastatic melanomaEnvironmental healthColorectal Cancer Treatments and StudiesColorectal Cancer Surgical TreatmentsColorectal and Anal Carcinomas